
Loading, please wait...

Loading, please wait...

Rapid neuroimaging guides acute ischemic stroke decisions, yet clinicians frequently encounter diagnostic discrepancies. In emergency neurovascular triage, computed tomography perfusion (CTP) delineates salvageable penumbra from irreversibly injured brain tissue. However, automated perfusion software can erroneously label viable oligemic tissue as dead parenchyma. This misleading radiological phenomenon, termed CTP core infarct overestimation or ghost infarct core, creates a major therapeutic hurdle. Consequently, clinicians risk denying life-saving mechanical thrombectomy to patients who actually possess salvageable tissue. Recent evidence reveals that circulating cardiovascular biomarkers, particularly admission N-terminal pro-brain natriuretic peptide (NT-proBNP), provide vital clues regarding this neuroimaging miscalculation.
Computed tomography perfusion maps rely heavily on cerebral blood flow thresholds, typically defining irreversible core infarction when relative cerebral blood flow drops below thirty percent. In clinical practice, this automated threshold assumes that severely diminished perfusion equates directly to nonviable cellular death. However, neuroscientists recognize that cellular viability depends on both the depth and duration of ischemia. When patients present during ultra-early time windows or harbor systemic hemodynamic impairment, acute hypoperfusion can dramatically suppress microvascular transit times without triggering immediate cellular necrosis.
Consequently, automated software packages frequently overestimate the definitive ischemic core size. When interventional radiologists subsequently achieve rapid, complete reperfusion, follow-up noncontrast computed tomography scans at twenty-four to forty-eight hours often reveal final infarcts substantially smaller than baseline estimates. International registries indicate that ghost infarct cores occur in six to thirty-eight percent of large vessel occlusion cases. Therefore, reliance solely on rigid volumetric thresholds can mistakenly exclude eligible stroke candidates from endovascular therapy. Neurointerventionalists and emergency specialists urgently require reliable clinical markers that signal potential overestimation before finalizing treatment eligibility.
To investigate clinical predictors of this neuroimaging discordance, researchers evaluated a prospective cohort of 353 acute ischemic stroke patients with anterior circulation large vessel occlusion. Every participant achieved satisfactory endovascular recanalization, defined as extended thrombolysis in cerebral infarction grade 2c or higher. In this cohort, fifty-two patients (14.8 percent) exhibited significant core infarct overestimation, where baseline CTP core volumes exceeded final 24- to 48-hour infarct volumes.
Multivariable logistic regression analysis demonstrated that elevated admission NT-proBNP independently predicted core overestimation, showing an adjusted odds ratio of 1.34. Furthermore, poor leptomeningeal collaterals increased overestimation odds more than threefold, yielding an adjusted odds ratio of 3.13. Cardiogenic embolism etiology also correlated independently with overestimation. Conversely, longer onset-to-imaging time demonstrated an inverse relationship, confirming that early presentations carry the highest risk of overestimation. Receiver operating characteristic analysis identified an optimal NT-proBNP cut-off value of 876 pg/ml. This cut-off yielded a sensitivity of 76.9 percent and an area under the curve of 0.813, establishing NT-proBNP as a potent diagnostic indicator.
Understanding the link between elevated natriuretic peptides and perfusion overestimation requires examining systemic cardiovascular and cerebral hemodynamics. Ventricular and atrial myocytes release NT-proBNP in response to increased myocardial wall stress, volume overload, and subclinical cardiac dysfunction. In acute ischemic stroke, markedly elevated NT-proBNP levels often indicate underlying cardioembolic sources, such as atrial fibrillation or cardiomyopathy. Consequently, these cardiac pathologies lead to reduced cardiac output and unstable systemic perfusion pressure.
When systemic perfusion pressure falters, cerebral autoregulation suffers, particularly in penumbral tissue bordering occluded vessels. Poor leptomeningeal collaterals further exacerbate local transit delays and decrease capillary flow velocity. Perfusion software interprets this profound, systemic microvascular delay as tissue necrosis because tracer arrival appears sluggish. However, neurons within these zones maintain cellular integrity if collateral channels preserve minimum metabolic thresholds. Therefore, when endovascular thrombectomy restores upstream vessel patency, these hypoperfused but viable territories re-establish microcirculation. The apparent core vanishes on subsequent imaging. Thus, elevated NT-proBNP serves as a physiological surrogate for impaired cardiac reserve and altered cerebral microhemodynamics.
These findings hold profound therapeutic implications for acute stroke treatment paradigms. Landmark clinical trials established mechanical thrombectomy as the standard of care for anterior circulation large vessel occlusions. Historically, trial protocols excluded patients presenting with large baseline ischemic cores, often set at core volumes greater than fifty or seventy milliliters. Although recent trials demonstrate that large-core strokes can still benefit from endovascular intervention, many centers continue applying strict volumetric exclusion criteria.
When automated CTP calculations overestimate core size, clinicians may inappropriately withhold thrombectomy from patients who harbor genuine salvageable tissue. The study underscores that an admission NT-proBNP level exceeding 876 pg/ml, especially alongside poor collaterals and rapid presentation, strongly flags potential imaging distortion. Clinicians should not abandon endovascular therapy based strictly on automated volumetric cut-offs in these patients. Instead, multidisciplinary teams must contextualize perfusion maps alongside noncontrast CT Alberta Stroke Program Early CT Scores and clinical severity. By recognizing the likelihood of CTP core overestimation, stroke teams can avoid denying life-saving recanalization to patients who retain substantial penumbral tissue.
Integrating biomarker assessment into acute stroke workflows enhances diagnostic accuracy and prevents treatment nihilism. Emergency physicians and neurologists should rapidly obtain baseline NT-proBNP measurements alongside routine cardiac and coagulation profiles upon hospital presentation. When point-of-care or rapid laboratory panels show NT-proBNP levels above 876 pg/ml in patients arriving within early time windows, teams should interpret massive CTP core infarcts with heightened caution.
Furthermore, neurointerventionalists must carefully scrutinize multiphase CT angiography images to evaluate collateral quality. If collateral status appears poor and the onset-to-imaging interval is short, automated CTP software is particularly vulnerable to ghost core generation. Under these circumstances, stroke teams should avoid relying on automated CTP printouts as absolute disqualifiers. Instead, physicians should prioritize noncontrast CT Alberta Stroke Program Early CT Scores and clinical vessel occlusion status to guide endovascular intervention. Additionally, post-procedure management must optimize cardiac output and maintain adequate mean arterial pressure, ensuring optimal perfusion to vulnerable tissue beds. Adopting this holistic approach ensures that neuroimaging artifacts do not compromise patient survival and long-term functional recovery.
Automated software calculates ischemic core using relative cerebral blood flow thresholds. During early time windows, severe microvascular hypoperfusion and impaired collateral flow can slow tracer arrival significantly. This sluggish flow mimics cellular necrosis on automated maps, even though neurons remain metabolically viable and recover fully following prompt endovascular recanalization.
Elevated admission NT-proBNP indicates systemic cardiac strain, cardioembolic etiology, and reduced cardiac output. Impaired central hemodynamics compromise cerebral collateral circulation and penumbral flow. Consequently, automated perfusion algorithms mistake this severe cardiac-driven flow delay for irreversible tissue death, generating false-positive core overestimation on baseline neuroimaging.
No, high CTP core volume should not automatically exclude stroke patients from mechanical thrombectomy. Perfusion overestimation frequently occurs in early presenters with poor collaterals and elevated NT-proBNP. Clinicians should evaluate noncontrast CT ASPECTS, clinical severity, and collateral scores before denying patients life-saving endovascular revascularization.
Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Elevated admission NT-proBNP (>876 pg/ml) independently predicts CTP core infarct overestimation in acute ischemic stroke. Understanding this ghost core phenomenon prevents inappropriate exclusion of eligible thrombectomy candidates with large vessel occlusion.
Today

A landmark study reveals that congenital DLK1 deficiency in women with a history of central precocious puberty causes visceral adiposity, mitochondrial dysfunction, oxidative stress, and neutrophil activation, highlighting the critical need for lifelong cardiometabolic surveillance.
Today

Estetrol (E4), a native fetal estrogen, offers a unique tissue-selective profile with minimal hepatic impact and lower thrombotic risk. This review highlights its clinical use in oral contraception, menopausal symptom management, and emerging applications across oncology and neurology.
Today

Explore revascularisation strategies in dialysis-dependent chronic limb-threatening ischaemia. This review examines surgical bypass vs endovascular therapy, BEST-CLI trial findings, procedural morbidity, conduit availability, and multidisciplinary decision-making for optimal limb salvage.
Today

A recent cross-sectional analysis reveals that over a quarter of randomized controlled trials for non-specific low back pain face discontinuation or unknown status, while more than 36% of completed trials remain unpublished, exposing notable reporting gaps in spine and musculoskeletal clinical research.
Today

This case report examines the longitudinal CBCT evolution of Stage 2 MRONJ in a 70-year-old woman on denosumab at the site of a pre-existing mandibular dense bone island. It emphasizes the radiographic features, differential diagnosis, and multidisciplinary strategies required for high-risk bone lesions.
Today